.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Teva
McKinsey
Chinese Patent Office
Fish and Richardson
Dow
Farmers Insurance
US Army
Queensland Health
Cerilliant

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,273,735

« Back to Dashboard

Details for Patent: 8,273,735

Title:Process for preparing benzazepine compounds or salts thereof
Abstract: This invention provides a process for preparing benzazepine compounds of the formula (1): wherein X.sup.1 is a halogen atom, R.sup.1 and R.sup.2 are a lower alkyl group, or salts thereof as well as intermediate benzoic acid compounds in high yield and high purity on industrial scale, which are useful as an intermediate for preparing a pharmaceutically active 2,3,4,5-tetrahydro-1H-1-benzazepine compound having vasopressin antagonistic activity. ##STR00001##
Inventor(s): Torisawa; Yasuhiro (Tokushima, JP), Abe; Kaoru (Tokushima, JP), Muguruma; Yasuaki (Tokushima, JP), Fujita; Shigekazu (Okazaki, JP), Ogawa; Hidenori (Tokushima, JP), Utsumi; Naoto (Tokushima, JP), Miyake; Masahiro (Tokushima, JP)
Assignee: Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)
Filing Date:Sep 01, 2006
Application Number:12/064,178
Claims:1. A process for producing a benzazepine compound of the formula (1): ##STR00028## wherein X.sup.1 is a halogen atom, R.sup.1 and R.sup.2 are independently a lower alkyl group, or salts thereof, which comprises reacting a benzazepine compound of the formula (2): ##STR00029## wherein X.sup.1 is as defined above, or a salt thereof with an amide compound of the formula (3): ##STR00030## wherein R.sup.1 and R.sup.2 are as defined above and X.sup.2 is a halogen atom, or a salt thereof in the presence of a carbonylating agent.

2. A process for producing a benzoic acid compound of the formula (4): ##STR00031## wherein R.sup.1 and R.sup.2 are independently a lower alkyl group, or a salt thereof, which comprises reacting an amide compound of the formula (11): ##STR00032## wherein R.sup.1 and R.sup.2 are as defined above, or a salt thereof, with a compound of the formula (19): X.sup.6COCOX.sup.7 (19) wherein X.sup.6 and X.sup.7 are independently a halogen atom.

3. A process for producing a benzoic acid compound of the formula (4): ##STR00033## wherein R.sup.1 and R.sup.2 are independently a lower alkyl group, or a salt thereof, which comprises oxidizing an amide compound of the formula (12): ##STR00034## wherein R.sup.1 and R.sup.2 are as defined above and X.sup.3 is a halogen atom, or a salt thereof.

4. A process for producing a benzoic acid compound of the formula (4): ##STR00035## wherein R.sup.1 and R.sup.2 are independently a lower alkyl group, or a salt thereof, which comprises hydrolyzing an amide compound of the formula (13): ##STR00036## wherein R.sup.1 and R.sup.2 are as defined above and X.sup.3 is a halogen atom, or a salt thereof.

5. A process for producing a benzoic acid compound of the formula (4): ##STR00037## wherein R.sup.1 and R.sup.2 are independently a lower alkyl group, or a salt thereof, which comprises oxidizing an amide compound of the formula (14): ##STR00038## wherein R.sup.1 and R.sup.2 are as defined above, or a salt thereof.

6. A process for producing a 2,3,4,5-tetrahydro-1H-1-benzazepine compound of the formula (10): ##STR00039## wherein X.sup.1 is a halogen atom, R.sup.1 and R.sup.2 are independently a lower alkyl group, or a salt thereof, which comprises reducing a benzazepine compound of the formula (1): ##STR00040## wherein R.sup.1, R.sup.2 and X.sup.1 are as defined above, or a salt thereof in the presence of a hydrogenating agent selected from the group consisting of lithium aluminum hydride, sodium borohydride, zinc borohydride, and diborane in an amount of 0.25 to 1 mole per 1 mole of the compound (1).

7. The process according to claim 6, wherein the hydrogenating agent is sodium borohydride which is used in an amount of 0.25 to 1 mole per 1 mole of the compound (1).

8. The process according to claim 7, wherein the hydrogenating agent is used in an amount of 0.25 to 0.5 mole per 1 mole of the compound (1).

9. The process according to claim 1, wherein the benzazepine compound (1) is 7-chloro-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahyd- ro-1H-1-benzazepin-5-one, or a salt thereof.

10. The process according to any one of claims 6, 7 and 8, wherein the 2,3,4,5-tetrahydro-1H-1-benzazepine compound (10) is 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-t- etrahydro-1H-1-benzazepine, or a salt thereof.

11. A benzazepine compound selected from 7-chloro-5-hydroxy-1-{2-methyl-4-[N-(2-methylbenzoyl)-N-(2-methyl-4-(2-me- thylbenzoylamino)benzoylamino]benzoyl}-2,3,4,5-tetrahydro-1H-1-benzazepine (Compound A) or a salt thereof, 7-chloro-5-hydroxy-1-{2-methyl-4-[2-methyl-4-(2-methylbenzoylamino)benzoy- lamino]-benzoyl}-2,3,4,5-tetrahydro-1H-1-benzazepine (Compound B) or a salt thereof, 7-chloro-5-[2-methyl-4-(2-methylbenzoylamino)benzoyloxy]-1-[2-methyl-4-(2- -methylbenzoylamino)benzoyl]-2,3-dihydro-1H-1-benzazepine (Compound C) or a salt thereof, or 7-chloro-5-[2-methyl-4-(2-methylbenzoylamino)benzoyloxy]-1-[2-methyl-4-(2- -methylbenzoyl-amino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine (Compound D) or a salt thereof.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Accenture
Colorcon
US Department of Justice
Moodys
Chubb
US Army
Federal Trade Commission
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot